AI NewsGo-to-marketReported

Isomorphic Labs raises $5 billion to push AI-designed drugs into trials

Isomorphic Labs, the Alphabet-owned company spun out of DeepMind, has raised $5 billion. The round takes its AI-designed therapies toward trials.

AI News

Editorial2 min read

LinkedInX

Why it mattersAI drug design is now funded at the same scale as a model lab. Buyers in regulated fields will see more bets like this one.

Isomorphic Labs is the drug design company Alphabet spun out of DeepMind. The company has raised $5 billion in a Series C round. Greenoaks and Sequoia Capital are co-leading. On its own page, Isomorphic says the money will scale its drug design engine. The company also plans to move more therapies toward clinical trials.

This is the company's second round in six months. The first was a $2.1 billion Series B. The total raised across the two rounds is $7.1 billion. That size matches a frontier model round. The field has been slow for most teams.

What the company says the money is for

The drug design engine Isomorphic uses is called IsoDDE. The announcement names it. The company's own statement says the round will "scale its proprietary drug design engine (IsoDDE)". It will also scale a "therapeutic candidate pipeline designed with AI". That is the only sentence about the pipeline. The post names no candidate drugs. It lists no specific disease targets on its own page. It does not say when a trial starts.

TechCrunch reports a Bloomberg figure for the valuation after the round: $50 billion. Bloomberg is the source for that number. The company itself did not confirm it. TechCrunch also writes that Andreessen Horowitz is a new investor. Alphabet, GV, CapitalG, Thrive Capital, MGX, Temasek and the UK Sovereign AI Fund are continuing from earlier rounds.

Who the pharma partners are, and what the company itself says

In its own page about the raise, Isomorphic names no pharma partner. TechCrunch's report says the company has partnerships with Eli Lilly, Johnson & Johnson and Novartis. TechCrunch also describes early preclinical work in oncology and immunology as "positive". None of that is on Isomorphic's own announcement. The pipeline detail is TechCrunch's reporting.

For a reader less close to biotech, the news is the round itself. Isomorphic has been running for five years. It has released no drug. It has now raised more money in two rounds in 2026 than many public biotech companies hold in cash. Chief executive Demis Hassabis also runs Google DeepMind. DeepMind won the 2024 Nobel Prize in Chemistry for AlphaFold. AlphaFold is the protein-structure work Isomorphic is built on.

The signal for a software team is the price of a specialised AI company in a regulated field. The same investors that fund model labs are now paying for an AI company whose customer is a drug regulator. The engineering job around such a system is a different shape of work. The main items are evidence trails, reproducible evaluation and auditable code. Chatty demos count for little.

Source

Reported byIsomorphic Labs

This item was written by an AI system from the linked source. Reveneau is responsible for what it publishes.

Share
LinkedInX
Start a project